Safety, efficacy and renal effect of febuxostat in patients with moderate-to-severe kidney dysfunction

Hypertension Research

Volumn 37, Issue 10, 2014, Pages 919-925

  Shibagaki, Yugo ^a   Ohno, Iwao ^b   Hosoya, Tatsuo ^b   Kimura, Kenjiro ^a  

^a ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

chronic kidney disease; febuxostat; safety

Indexed keywords

FEBUXOSTAT; URIC ACID; ANTIGOUT AGENT; THIAZOLE DERIVATIVE;

AGED; ARTICLE; CHRONIC KIDNEY DISEASE; CONSTIPATION; DIASTOLIC BLOOD PRESSURE; DRUG DOSE ESCALATION; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EDEMA; FEMALE; GLOMERULUS FILTRATION RATE; GOUT; HEART PALPITATION; HUMAN; HYPERURICEMIA; MAJOR CLINICAL STUDY; MALE; NEUROPATHIC PAIN; OPEN STUDY; PARESTHESIA; PROSPECTIVE STUDY; PROTEIN URINE LEVEL; PROTEINURIA; PULSE RATE; SEVERE RENAL IMPAIRMENT; THORAX PAIN; TREATMENT DURATION; URIC ACID BLOOD LEVEL; BIOASSAY; BLOOD; BLOOD PRESSURE; DOSE RESPONSE; DRUG EFFECTS; MIDDLE AGED; RENAL INSUFFICIENCY, CHRONIC;

AGED; BLOOD PRESSURE; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDPOINT DETERMINATION; FEMALE; GLOMERULAR FILTRATION RATE; GOUT SUPPRESSANTS; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROTEINURIA; RENAL INSUFFICIENCY, CHRONIC; THIAZOLES; URIC ACID;

EID: 84906242507     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1038/hr.2014.107     Document Type: Article

References (24)

1. Iseki K, Iseki C, Kinjo K. Changes in serum uric acid have a reciprocal effect on eGFR change: a 10-year follow-up study of community-based screening in Okinawa, Japan. Hypertens Res 2013; 36: 650-654.
2. Kang DH, Chen W. Uric acid and chronic kidney disease: new understanding of an old problem. Semin Nephrol 2011; 31: 447-452.
3. Liu WC, Hung CC, Chen SC, Yeh SM, Lin MY, Chiu YW, Kuo MC, Chang JM, Hwang SJ, Chen HC. Association of hyperuricemia with renal outcomes, cardiovascular disease, and mortality. Clin J Am Soc Nephrol 2012; 7: 541-548.
4. Ohta Y, Tsuchihashi T, Kiyohara K, Oniki H. Increased uric acid promotes decline of the renal function in hypertensive patients: a 10-year observational study. Intern Med 2013; 52: 1467-1472.
5. Keenan RT, O'Brien WR, Lee KH, Crittenden DB, Fisher MC, Goldfarb DS, Krasnokutsky S, Oh C, Pallinger MH. Prevalence of contraindications and prescription of pharmacologic therapies for gout. Am J Med 2011; 124: 155-163.
6. Curiel RV, Guzman NJ. Challenges associated with the management of gouty arthritis in patients with chronic kidney disease: a systematic review. Semin Arthritis Rheum 2012; 42: 166-178.
7. Becker MA, Schumacher HR, Espinoza LR, Wells AF, MacDonald P, Lloyd E, Lademacher C. The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Res Ther 2010; 12: R63.
8. Hosoya T, Ohno I. A repeated oral administration study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with impaired renal function in Japan: pharmacokinetic and pharmacodynamic study. J Clin Rheumatol 2011; 17: S27-S34.
9. Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, Yamagata K, Tomino Y, Yokoyama H, Hishida ACollaborators developing the Japanese equation for estimated GFR. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 2009; 53: 982-992.
10. Yamanaka HJapanese Society of Gout and Nucleic Acid Metabolism. Japanese guideline for the management of hyperuricemia and gout: second edition. Nucleosides Nucleotides Nucleic Acids 2011; 30: 1018-1029.
11. Kobayashi S, Ogura M, Hosoya T. Acute neutropenia associated with initiation of febuxostat therapy for hyperuricaemia in patients with chronic kidney disease. J Clin Pharm Ther 2013; 38: 258-261.
12. Grabowski BA, Khosravan R, Vernillet L, Mulford DJ. Metabolism and excretion of [14C] febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase, in healthy male subjects. J Clin Pharmacol 2011; 51: 189-201.
13. Painsansinsup T, Breitenstein MK, Schousboe JT. Association between adverse reactions to allopurinol and exposures to high maintenance doses: implications for management of patients using allopurinol. J Clin Rheumatol 2013; 19: 180-186.
14. Schumacher Jr HR, Becker MA, Wortmann RL, Macdonald PA, Hunt B, Streit J, Lademacher C, Joseph-Ridge N. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum 2008; 59: 1540-1548.
15. Nakaya I, Namikoshi T, Tsuruta Y, Nakata T, Shibagaki Y, Onishi Y, Fukuhara S, School of Designing Clinical Study for Nephrologists and Dialysis Physicians. Management of asymptomatic hyperuricaemia in patients with chronic kidney disease by Japanese nephrologists: a questionnaire survey. Nephrology (Carlton) 2011; 16: 518-521.
16. Iseki K, Oshiro S, Tozawa M, Iseki C, Ikemiya Y, Takishita S. Significance of hyperuricemia on the early detection of renal failure in a cohort of screened subjects. Hypertens Res 2001; 24: 691-697.
17. Iseki K, Ikemiya Y, Inoue T, Iseki C, Kinjo K, Takishita S. Significance of hyperuricemia as a risk factor for developing ESRD in a screened cohort. Am J Kidney Dis 2004; 44: 642-650.
18. Badve SV, Brown F, Hawley CM, Johnson DW, Kanellis J, Rangan GK, Perkovic V. Challenges of conducting a trial of uric-acid-lowering therapy in CKD. Nat Rev Nephrol 2011; 7: 295-300.
19. Whelton A, Macdonald PA, Zhao L, Hunt B, Gunawardhana L. Renal function in gout: long-term treatment effects of febuxostat. J Clin Rheumatol 2011; 17: 7-13.
20. Sezai A, Soma M, Nakata K, Hata M, Yoshitake I, Wakui S, Hata H, Shiono M. Comparison of febuxostat and allopurinol for hyperuricemia in cardiac surgery patients (NU-FLASH Trial). Circ J 2013; 77: 2043-2049.
21. Feig DI, Soletsky B, Johnson RJ. Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial. JAMA 2008; 300: 924-932.
22. Tsuda H, Kawada N, Kaimori JY, Kitamura H, Moriyama T, Rakugi H, Takahara S, Isaka Y. Febuxostat suppressed renal ischemia-reperfusion injury via reduced oxidative stress. Biochem Biophys Res Commun 2012; 427: 266-272.
23. Omori H, Kawada N, Inoue K, Ueda Y, Yamamoto R, Matsui I, Kaimori J, Takabatake Y, Moriyama T, Isaka Y, Rakugi H. Use of xanthine oxidase inhibitor febuxostat inhibits renal interstitial inflammation and fibrosis in unilateral ureteral obstructive nephropathy. Clin Exp Nephrol 2012; 16: 549-556.
24. Johnson RJ, Nakagawa T, Jalal D, Sanchez-Lozada LG, Kang DH, Ritz E. Uric acid and chronic kidney disease: which is chasing which? Nephrol Dial Transplant 2013; 28: 2221-2228.